5 completed, 1 recruiting, 1 terminated. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Recruiting 1, Terminated 1 |
| Phase 1 | 3 | Completed 3 |
Follow SBE4-beta-cyclodextrin: new trials by email Literature Review of SBE4-beta-cyclodextrin trials Research Report on SBE4-beta-cyclodextrin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD. Experiment 1: Three-day aversive conditioning, extinction, and extinction retention testing paradigm, Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer., Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm - Post Traumatic Stress Disorder | Phase 2 | Recruiting | Massachusetts General Hospital | 96 | 2025-08-04 | 2025-11-05 |
| Pharmacokinetic Study for IV Allopregnanolone PK-1 Good Manufacturing Practices (GMP) allopregnanolone (Allo) with Dexolve in 0.9% saline for infusion manufactured by the University of California, Davis, PK-2 GMP allopregnanolone (Allo) with Dexolve in 0.9% saline for infusion manufactured by the University of California, Davis. - Pharmacokinetic Study, Post Traumatic Stress Disorder | Phase 2 | Terminated | Boston University | 11 | 2022-03-04 | 2026-06-02 |
| A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation LGD-6972 Solution, LGD-6972 Capsules - Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Completed | Ligand Pharmaceuticals | 12 | 2016-02-01 | 2016-05-18 |
| Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus LGD-6972, Placebo (Captisol ®) - Type 2 Diabetes Mellitus | Phase 1 | Completed | Ligand Pharmaceuticals | 48 | 2014-10-01 | 2015-06-11 |
| Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus LGD-6972, Placebo (Captisol®) - Type 2 Diabetes Mellitus | Phase 1 | Completed | Ligand Pharmaceuticals | 56 | 2013-11-01 | 2014-09-25 |
| Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis Budesonide + Azelastine, Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Ligand Pharmaceuticals | 108 | 2008-02-01 | 2012-10-04 |
| Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of AR Budesonide, Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Ligand Pharmaceuticals | 65 | 2007-02-01 | 2012-10-04 |
Diabetes Mellitus, Type 2 (3) · Rhinitis, Allergic, Seasonal (2) · Stress Disorders, Post-Traumatic (2) · Wounds and Injuries (1)
Ligand Pharmaceuticals (5) · Boston University (1) · Massachusetts General Hospital (1)
United States (5) · Canada (2)
Deepen Patel, MD (2) · Ann M Rasmusson, MD (1) · Douglas K Logan, M.D. (1) · Keith Marschke, Ph.D. (1) · Lukasz Biernat, M.D. (1)
R01MH122867 (2)